Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Zeiser R, 2015, Leukemia  (Link to abstract)                                            


Ruxolitinib is a JAK 1 /2 inhibitor for treating myelofibrosis, which was also reported to be effective for treatment of GVHD in mouse models. This study is a retrospective survey of the outcomes of patients who received ruxolitinib as salvage therapy for corticosteroid refractory GVHD. Data was collected from 19 centers in Europe and the USA. A total of 95 patients were included for analysis (acute GVHD n=54, chronic GVHD n=41). Overall response rate was 81.5% and 85.4%, for aGVHD and for cGVHD, respectively. 6 month survival rates [NW5] were 79% and 97.4%for aGVHD and cGVHD, respectively. Adverse events observed included increased risk of CMV reactivation, and cytopenias.


* Ruxolitinib appears to be a promising new agent for steroid resistant acute and chronic GVHD in a retrospective review.